Pfizer’s chief strategist Andrew Baum, M.D., is leaving his post two years after pivoting from a career-long tenure as a ...

There might be room for two titans in the obesity business, but a third player might have a uniquely marketable option.

April 20 (Reuters) - Pfizer's Chief Strategy and Innovation Officer, Andrew Baum, is transitioning to a new role and will ...

Pfizer (PFE) executive Andrew Baum, hired in 2024 as its Chief Strategy and Innovation Officer to overhaul the company’s strategic direction, is leaving the drugmaker later this year, according to a ...

Under the Prescription Drug User Fee Act, the FDA has set a target action date of 17 August 2026.

The healthcare giant has been investing heavily in its future growth.

U.S. Food and Drug Administration "enforcement in the social media space has historically been somewhat limited, but recent ...

Pfizer executive Andrew Baum, a former Citi analyst, has left his role as an executive vice president and chief strategy and ...

The FDA has scolded Pfizer over Facebook ads for the cancer drug Adcetris, accusing the Big Pharma of failing to adequately ...

Before deciding to walk away from the building, Pfizer tried to list nearly half of the 164,000-square-foot campus for ...

A $500,000 retirement portfolio spread across five income-focused stocks can generate a blended yield of roughly 7.4%, ...

Global drug maker Pfizer (PFE) and biotech firm Amgen (AMGN), each valued at over HK$1T ($153B), are among 22 strategic ...